What the label states, the lot delivers — net peptide mass, not gross powder weight, purity reported as measured rather than rounded up, and a Certificate of Analysis for every lot.
Net peptide mass, not powder weight; purity as measured, not rounded up; a COA per lot.
Net peptide + purity not rounded up. COA per lot.
FDA PCAC reviews 7 peptides for the 503A bulks list (BPC-157, KPV, TB-500, MOTs-C, Emideltide, Semax, Epitalon). Read our compounder's decision tree. Read our briefing →
FDA PCAC reviews 7 peptides for the 503A bulks list in July. Read →
FDA PCAC: 7 peptides under review. Read →
Modified GRF 1-29 · GHRH analog
Vialdyne primary owner
This is the primary Vialdyne page for pharmacy buyers qualifying CJC-1295 no-DAC for GH-axis workflows and combination-vial planning. The page focuses on release evidence, counter-ion, fill ladder, combination options, and QA-file clarity.
Overview
CJC-1295 without DAC, also catalogued as Modified GRF 1-29 or ModGRF 1-29, is a 29-residue GHRH analogue carrying four engineered substitutions (Ala2 to D-Ala, Asn8 to Gln, Gly15 to Ala, Met27 to Leu) that block DPP-4 cleavage and slow serum protease degradation. Receptor pharmacology is GHRH-receptor-mediated, and the resulting GH-release pattern is pulsatile and closely resembles native physiological secretion, in contrast to the DAC variant, whose covalent albumin conjugation pushes plasma half-life into the once-weekly range and flattens the pulse architecture. For compounding pharmacy buyers, Vialdyne releases CJC-1295 no-DAC as the lyophilised acetate against a ≥99.0% main-peak HPLC specification. The no-DAC form is most commonly paired with a GHSR-axis agonist (Ipamorelin, occasionally GHRP-2 or GHRP-6) in dual-pathway compounding protocols; the canonical CJC-1295 + Ipamorelin pairing is supplied directly as a pre-blended co-lyophilised vial under the cjc-1295-ipamorelin SKU, which removes the in-cleanroom blending step and certifies the actual ratio on the released-batch COA. The companion [CJC-1295 + Ipamorelin pharmacology article](/insights/cjc-1295-ipamorelin-blend-pharmacology-guide) covers the dual-pathway rationale in detail. Catalogue strengths are 2, 5, and 10 mg; the 2 and 5 mg fills are the typical dispensing vials in 503A workflows.
Applications & buyer fit
GH-axis peptides ship to two main buyer types: compounding pharmacies dispensing under physician supervision, and research labs studying somatotropic-axis pharmacology. Pharmacies typically want sterile-filled vials with the full release packet (sterility, endotoxin, CCI); labs typically want loose-format lyophilized powder with sequence verification. Blends (the CJC-1295 / Ipamorelin combination is the canonical example) are usually co-lyophilized rather than solution-mixed for potency stability.
Sourced for
Buyer fit
Documentation that ships
Procurement note: Sterile-filled vials are available with the full release packet (sterility, endotoxin, CCI); loose lyophilized powder ships with sequence verification.
Primary buyer fit: academic and contract research laboratories and 503A / 503B compounding pharmacies.
Specifications
Certificate of Analysis
Published released-batch COAs for CJC-1295 (no DAC), every lot HPLC-verified. These are previews — request the full high-resolution certificate for any lot.
VerifiedRequest full COA →CJC-1295 (no DAC)
VD260428-CND10055 · 99.17%
VerifiedRequest full COA →CJC-1295 (no DAC)
VD260428-CND053 · 99.14%
VerifiedRequest full COA →CJC-1295 (no DAC)
VD260428-CND5054 · 98.96%
Regulatory note
Sold as a pharmaceutical-grade active for research and for compounding-pharmacy formulation where local regulations permit (notably 503A / 503B in the United States and analogous regimes elsewhere). Not a finished dosage form. Sterile-filled vials are available with full release documentation; the buyer is responsible for verifying scheduling and dispense requirements in the destination market.
Frequently asked questions
The backbone is the same Modified GRF 1-29 sequence in both, but the DAC version carries an additional maleimido-propionyl modification at Lys30. In serum, the maleimide forms a covalent bond with the free thiol of Cys34 on human serum albumin, producing a circulating peptide-albumin conjugate that extends half-life from roughly 30 minutes (no-DAC) to about 6-8 days (DAC). The pharmacology is therefore fundamentally different: no-DAC produces a pulsatile GH-release pattern that mirrors physiological secretion, while DAC produces sustained GH elevation that overrides the natural pulse architecture. Most 503A compounding workflows and pulse-pharmacology research use the no-DAC form; sustained-elevation contexts are where DAC fits.
Because two receptor pathways converge on the same somatotroph cells and produce additive output. CJC-1295 signals through the GHRH receptor; Ipamorelin signals through the GHSR (ghrelin receptor). Combining a GHRH-pathway agonist with a GHSR-pathway agonist produces a measurably larger GH pulse than either component alone at matched individual doses. The standard combined-product ratio is 1:1 by mass (2+2 mg or 5+5 mg per vial are the typical fills). Vialdyne ships this as a pre-blended co-lyophilised vial under the cjc-1295-ipamorelin SKU, which is operationally preferred over having the receiving pharmacy combine two reconstituted vials inside the cleanroom because the released-batch COA certifies the actual ratio in the cake rather than just the nominal target.
The lyophilised cake dissolves cleanly in bacteriostatic water for injection at standard reconstitution concentrations. Solution stability at -20 C as single-use aliquots is reasonable, but the dominant operational driver of measured-potency loss in this class is freeze-thaw cycling, not slow temperature drift, so the practical guidance is to sub-divide immediately after reconstitution into the smallest workable single-use volumes and cap the cumulative thaw count at three or fewer per aliquot. The lyophilised vial itself rolls under the standard 24-month re-test window at -20 C, and the released-batch COA carries the documented re-test date for pharmacies planning recurring procurement cycles.
Related peptides
Ghrelin / GHSR pathway GH-release peptide
GH-axis blend (CJC-1295 no DAC + Ipamorelin)
29-mer
GHRH 1-29 fragment
Long-acting GHRH analog with Drug Affinity Complex
